("Faron" or the "Company")
Faron hosts virtual R&D Day today
Company announcement,
· Prof.
· Ass. Prof. Maija Hollmén,
· Dr.
Clevegen
Clevegen is Faron's wholly-owned novel precision cancer immunotherapy, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. As announced this morning, the
Presentations will include:
· A comprehensive review of myeloid cell plasticity in cancer formation
· Clevegen (bexmarilimab) induced immune activation in patients from the MATINS trial
· A review of the safety and efficacy results from Part I of the MATINS study
· An update on Part II cohorts and the bexmarilimab clincial expansion plans
Traumakine
Traumakine is currently under development for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS). Faron will provide an overview of data generated to date (including insights into the detrimental effect of corticosteroids on ARDS patients), the next steps in Traumakine's clincial development and an overview of the ongoing clinical trials including:
· The REMAP-CAP trial
· The
· A new US based study called HIBISCUS, which is focusing on ICU entered patients with acute respiratory failure caused by viral infection (e.g. COVID-19, influenza). Details of this new study were announced earlier today and are also summarised below
· An update on manufacturing
About HIBISCUS
Human Interferon Beta In Severe CoronavirUS (HIBISCUS) study is a phase II/III pivotal, randomized, placebo controlled Traumakine study in severely ill COVID-19 patients. The study aims to recruit 350 patients with 1:1 randomization and patients will be followed for ventilation free days (VFD) and mortality over the 28 day period post first dosing. No corticosteroid use will be accepted in this study which is expected to enroll patients over 6-8 months throughout the US with many significant hospitals participating. The study's principal investigator will be Prof.
Agenda and presentations
Time Presentation Presenter
(BST)
13.00 Faron corporate review - update on Markku JalkanenCEO, Faron
R&D strategy and pipeline Pharmaceuticals
developments
13.10 Myeloid cell plasticity and cancer
development MantovaniHumanitas
University,Milan,
13.30 Clever-1 blocking induced immune Ass. Prof. Maija
activation HollménMediCity,
UniversityFinland
13.45 MATINS study Part I safety and Dr. Petri BonoTerveystalo,
clinical efficacy
14.00 Clevegen clinical development Dr. Matti KarvonenFaron
14.15 Traumakine overview Dr. Juho JalkanenFaron
14.25 Summary
14:30 Q&A
To register for the event and receive the webcast details please contact
A replay will be made available on the investor section of Faron's website shortly after the event.
For more information please contact:
Dr
investor.relations@faron.com
Phone: +44 207 886 2500
Phone: +358 (0)40 555 4727
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations, Inc.
Phone: +(1)212 362 1200
Email: Julie.Seidel@sternir.com
About
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in
https://news.cision.com/faron-pharmaceuticals-oy/r/faron-hosts-virtual-r-d-day-today,c3135061
(c) 2020 Cision. All rights reserved., source